Lexeo Therapeutics surges 9.33% on Raymond James Strong Buy rating.

Lexeo Therapeutics surged 9.33% in pre-market trading on December 19, 2025, driven by a fresh analyst rating that underscored confidence in its growth trajectory.

Raymond James initiated coverage with a "Strong Buy" rating and a $25 price target, marking a significant upgrade from recent "Buy" or "Overweight" assessments. Analyst Christopher Raymond highlighted the stock's potential to deliver substantial returns, aligning with a broader trend of positive sentiment. Earlier in December, Chardan Capital and Cantor Fitzgerald had also reiterated or maintained bullish stances, with price targets ranging from $17 to $19. This cumulative analyst support reflects optimism about Lexeo’s clinical-stage genetic medicine pipeline targeting high-unmet-need diseases.

Market expectations remain elevated, as the average of 10 analyst price targets stands at $19.40, implying over 100% upside from current levels. The stock’s pre-market rally suggests investors are responding to the latest ratings, which reinforce Lexeo’s positioning in the gene therapy sector amid ongoing R&D advancements.

Lexeo’s recent performance is also drawing comparisons to similar biotech companies that have seen significant growth after receiving favorable analyst ratings. The firm is currently in phase 2 clinical trials for its lead candidate, and positive results could further boost investor confidence. Analysts are also eyeing the company’s balance sheet and R&D spending as key indicators of long-term value.